ARMATA PHARMACEUTICALS INC
NYSE: ARMP (Armata Pharmaceuticals, Inc.)
Last update: 17 hours ago1.28
-0.04 (-3.03%)
| Previous Close | 1.32 |
| Open | 1.29 |
| Volume | 9,618 |
| Avg. Volume (3M) | 13,622 |
| Market Cap | 46,314,368 |
| Price / Book | 4.06 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Operating Margin (TTM) | -853.36% |
| Diluted EPS (TTM) | -0.890 |
| Quarterly Revenue Growth (YOY) | -19.20% |
| Current Ratio (MRQ) | 0.230 |
| Operating Cash Flow (TTM) | -37.55 M |
| Levered Free Cash Flow (TTM) | -29.40 M |
| Return on Assets (TTM) | -28.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Armata Pharmaceuticals, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 70.25% |
| % Held by Institutions | 3.84% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Edgewood Management Llc | 31 Dec 2024 | 100,000 |
| Seacrest Wealth Management, Llc | 31 Dec 2024 | 34,954 |
| Captrust Financial Advisors | 31 Dec 2024 | 13,140 |
| Group One Trading Llc | 31 Dec 2024 | 11,614 |
| Tower Research Capital Llc (Trc) | 31 Dec 2024 | 3,312 |
| Date | Type | Details |
|---|---|---|
| 20 Mar 2025 | Announcement | Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update |
| 12 Mar 2025 | Announcement | Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva |
| 11 Mar 2025 | Announcement | Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |